NASDAQ: EQEquillium Inc Stock
$0.93-0.05 (-5.1%)
Updated Sep 6, 2024
EQ Price
$0.93
Fair Value Price
N/A
Market Cap
$32.80M
52 Week Low
$0.45
52 Week High
$3.25
P/E
-3.86x
P/B
1.46x
P/S
0.57x
PEG
N/A
Dividend Yield
N/A
Revenue
$42.62M
Earnings
-$8.32M
Gross Margin
100%
Operating Margin
-18.31%
Profit Margin
-19.5%
Debt to Equity
0.91
Operating Cash Flow
-$16M
Beta
0.41
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
EQ Overview
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how EQ scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EQ is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EQ is good value based on its book value relative to its share price (1.46x), compared to the US Biotechnology industry average (6.22x)
P/B vs Industry Valuation
EQ is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more EQ due diligence checks available for Premium users.
Be the first to know about important EQ news, forecast changes, insider trades & much more!
EQ News
Valuation
EQ price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.86x
Industry
-46.85x
Market
24.57x
EQ price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.46x
Industry
6.22x
EQ is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EQ's financial health
Profit margin
Revenue
$13.9M
Net Income
$468.0k
Profit Margin
3.4%
EQ's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
EQ's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$42.9M
Liabilities
$20.4M
Debt to equity
0.91
EQ's short-term assets ($41.89M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EQ's short-term assets ($41.89M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EQ's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
EQ's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$730.0k
Investing
-$1.4M
Financing
$91.0k
EQ's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EQ vs Biotech Stocks
Equillium Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.